DFTX · Definium Therapeutics Inc. Common Shares
View on chartInsiders & Stakes
| Robert Barrow Chief Executive Officer | ▼ Sell | Open Market | 2,213,090 Shares held | 9/25/2026 | View profile |
| Hu Cynthia W. Chief Legal Officer&Secretary | ▲ Buy | Grant | 1,200,000 Shares held | 3/24/2022 | View profile |
| Daniel Karlin Chief Medical Officer | ▼ Sell | Open Market | 792,846 Shares held | 9/25/2026 | View profile |
| Mark Sullivan Chief Legal Officer | ▼ Sell | Open Market | 494,228 Shares held | 9/25/2026 | View profile |
| Brandi Roberts Chief Financial Officer | ▼ Sell | Open Market | 394,528 Shares held | 9/25/2026 | View profile |
| Matthew T. Wiley Chief Commercial Officer | ▼ Sell | Open Market | 359,036 Shares held | 9/25/2026 | View profile |
| Greenway Schond L. CFO | ▼ Sell | Tax Withholding | 211,057 Shares held | 3/25/2024 | View profile |
| Wernli Miri Halperin Executive President | ▼ Sell | Tax Withholding | 202,405 Shares held | 8/21/2024 | View profile |
| Brigid Makes CFO | ▲ Buy | Grant | 158,706 Shares held | 6/1/2022 | View profile |
| Liao Carrie VP, Controller&Acct Principal | ▼ Sell | Open Market | 144,923 Shares held | 3/25/2025 | View profile |
| Roger Crystal Director | ▲ Buy | Grant | 24,289 Shares held | 6/11/2026 | View profile |
| Suzanne Louise Bruhn Director | ▲ Buy | Grant | 24,289 Shares held | 6/11/2026 | View profile |
| Carol A. Vallone Director | ▲ Buy | Option Exercise | 22,296 Shares held | 9/18/2026 | View profile |
| Andreas Krebs Director | ▲ Buy | Option Exercise | 21,402 Shares held | 9/18/2026 | View profile |
| David W. Gryska Director | ▲ Buy | Grant | 19,900 Shares held | 6/11/2026 | View profile |
| Roger Adsett Chief Operating Officer | ▲ Buy | Grant | 3,555 Shares held | 6/11/2026 | View profile |
Transaction History
| Daniel Karlin | ▼ Sell | Open Market | 10,853 | $397K | 9/25/2026 |
| Robert Barrow | ▼ Sell | Open Market | 31,550 | $1.2M | 9/25/2026 |
| Matthew T. Wiley | ▼ Sell | Open Market | 3,097 | $113K | 9/25/2026 |
| Mark Sullivan | ▼ Sell | Open Market | 14,051 | $514K | 9/25/2026 |
| Brandi Roberts | ▼ Sell | Open Market | 3,377 | $123K | 9/25/2026 |
| Carol A. Vallone | ▲ Buy | Option Exercise | 1,086 | $39K | 9/18/2026 |
| Andreas Krebs | ▲ Buy | Option Exercise | 1,629 | $58K | 9/18/2026 |
| Matthew T. Wiley | ▲ Buy | Grant | 125,000 | $0 | 9/14/2026 |
| Mark Sullivan | ▲ Buy | Grant | 125,000 | $0 | 9/14/2026 |
| Brandi Roberts | ▲ Buy | Grant | 125,000 | $0 | 9/14/2026 |
| Daniel Karlin | ▲ Buy | Grant | 200,000 | $0 | 9/14/2026 |
| Robert Barrow | ▲ Buy | Grant | 750,000 | $0 | 9/14/2026 |
| Robert Barrow | ▼ Sell | Open Market | 19,023 | $722K | 9/3/2026 |
| Robert Barrow | ▲ Buy | Grant | 40,000 | $0 | 9/2/2026 |
| Robert Barrow | ▲ Buy | Grant | 375,000 | $0 | 8/12/2026 |
| Daniel Karlin | ▲ Buy | Grant | 100,000 | $0 | 8/12/2026 |
| Mark Sullivan | ▲ Buy | Grant | 62,500 | $0 | 8/12/2026 |
| Matthew T. Wiley | ▲ Buy | Grant | 62,500 | $0 | 8/12/2026 |
| Brandi Roberts | ▲ Buy | Grant | 62,500 | $0 | 8/12/2026 |
| Mark Sullivan | ▼ Sell | Open Market | 13,008 | $586K | 6/25/2026 |
| Brandi Roberts | ▼ Sell | Open Market | 3,013 | $136K | 6/25/2026 |
| Robert Barrow | ▼ Sell | Open Market | 29,208 | $1.3M | 6/25/2026 |
| Daniel Karlin | ▼ Sell | Open Market | 10,035 | $452K | 6/25/2026 |
| Matthew T. Wiley | ▼ Sell | Open Market | 2,867 | $129K | 6/25/2026 |
| Matthew T. Wiley | ▲ Buy | Grant | 62,500 | $0 | 6/22/2026 |
| Robert Barrow | ▲ Buy | Grant | 375,000 | $0 | 6/22/2026 |
| Brandi Roberts | ▲ Buy | Grant | 62,500 | $0 | 6/22/2026 |
| Mark Sullivan | ▲ Buy | Grant | 62,500 | $0 | 6/22/2026 |
| Daniel Karlin | ▲ Buy | Grant | 100,000 | $0 | 6/22/2026 |
| Roger Crystal | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 |
| David W. Gryska | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 |
| Carol A. Vallone | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 |
| Andreas Krebs | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 |
| Roger Adsett | ▲ Buy | Grant | 3,555 | $0 | 6/11/2026 |
| Suzanne Louise Bruhn | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 |
| Daniel Karlin | ▼ Sell | Open Market | 8,018 | $148K | 3/25/2026 |
| Mark Sullivan | ▼ Sell | Open Market | 10,702 | $198K | 3/25/2026 |
| Robert Barrow | ▼ Sell | Open Market | 24,431 | $451K | 3/25/2026 |
| Matthew T. Wiley | ▲ Buy | Grant | 115,000 | $0 | 2/3/2026 |
| Brandi Roberts | ▲ Buy | Grant | 150,000 | $0 | 2/3/2026 |
| Mark Sullivan | ▲ Buy | Grant | 125,000 | $0 | 2/3/2026 |
| Daniel Karlin | ▲ Buy | Grant | 150,000 | $0 | 2/3/2026 |
| Robert Barrow | ▲ Buy | Grant | 320,000 | $0 | 2/3/2026 |
| Daniel Karlin | ▼ Sell | Open Market | 5,600 | $74K | 12/26/2025 |
| Robert Barrow | ▼ Sell | Open Market | 25,791 | $339K | 12/26/2025 |
| Mark Sullivan | ▼ Sell | Open Market | 11,276 | $148K | 12/26/2025 |
| Mark Sullivan | ▼ Sell | Open Market | 11,278 | $110K | 9/25/2025 |
| Robert Barrow | ▼ Sell | Open Market | 25,797 | $252K | 9/25/2025 |
| Daniel Karlin | ▼ Sell | Open Market | 7,704 | $75K | 9/25/2025 |
| Mark Sullivan | ▼ Sell | Open Market | 11,491 | $78K | 6/25/2025 |
| Daniel Karlin | ▼ Sell | Open Market | 7,848 | $53K | 6/25/2025 |
| Robert Barrow | ▼ Sell | Open Market | 26,491 | $180K | 6/25/2025 |
| Robert Barrow | ▼ Sell | Open Market | 21,208 | $143K | 3/25/2025 |
| Daniel Karlin | ▼ Sell | Open Market | 6,836 | $46K | 3/25/2025 |
| Mark Sullivan | ▼ Sell | Open Market | 6,576 | $44K | 3/25/2025 |
| Liao Carrie | ▼ Sell | Open Market | 2,347 | $16K | 3/25/2025 |
| Robert Barrow | ▲ Buy | Grant | 350,000 | $0 | 3/12/2025 |
| Daniel Karlin | ▲ Buy | Grant | 115,000 | $0 | 3/12/2025 |
| Mark Sullivan | ▲ Buy | Grant | 150,000 | $0 | 3/12/2025 |
| Liao Carrie | ▲ Buy | Grant | 50,000 | $0 | 3/12/2025 |
| Robert Barrow | ▼ Sell | Open Market | 19,106 | $142K | 12/26/2024 |
| Liao Carrie | ▼ Sell | Open Market | 2,273 | $17K | 12/26/2024 |
| Daniel Karlin | ▼ Sell | Open Market | 6,643 | $49K | 12/26/2024 |
| Mark Sullivan | ▼ Sell | Open Market | 4,519 | $34K | 12/26/2024 |
| David W. Gryska | ▲ Buy | Open Market | 2,500 | $18K | 12/5/2024 |
| Liao Carrie | ▼ Sell | Open Market | 2,352 | $14K | 9/25/2024 |
| Robert Barrow | ▼ Sell | Open Market | 19,771 | $118K | 9/25/2024 |
| Daniel Karlin | ▼ Sell | Open Market | 6,871 | $41K | 9/25/2024 |
| Mark Sullivan | ▼ Sell | Open Market | 4,430 | $26K | 9/25/2024 |
| David W. Gryska | ▲ Buy | Open Market | 3,500 | $21K | 8/23/2024 |
| Wernli Miri Halperin | ▲ Buy | Option Exercise | 50,000 | $185K | 8/21/2024 |
| Wernli Miri Halperin | ▼ Sell | Tax Withholding | 32,595 | $201K | 8/21/2024 |
| Robert Barrow | ▲ Buy | Open Market | 500 | $3K | 8/20/2024 |
| Robert Barrow | ▲ Buy | Open Market | 500 | $3K | 8/19/2024 |
| Daniel Karlin | ▼ Sell | Open Market | 6,925 | $50K | 6/25/2024 |
| Mark Sullivan | ▼ Sell | Open Market | 17,854 | $129K | 6/25/2024 |
| Robert Barrow | ▼ Sell | Open Market | 15,659 | $113K | 6/25/2024 |
| Greenway Schond L. | ▼ Sell | Tax Withholding | 5,560 | $54K | 3/25/2024 |
| Daniel Karlin | ▼ Sell | Open Market | 6,578 | $62K | 3/25/2024 |
| Robert Barrow | ▼ Sell | Open Market | 16,519 | $157K | 3/25/2024 |
| Daniel Karlin | ▼ Sell | Open Market | 6,774 | $25K | 12/26/2023 |
| Robert Barrow | ▼ Sell | Open Market | 13,237 | $48K | 12/26/2023 |
| Greenway Schond L. | ▼ Sell | Open Market | 5,652 | $21K | 12/26/2023 |
| Robert Barrow | ▼ Sell | Open Market | 5,268 | $19K | 9/25/2023 |
| Robert Barrow | ▼ Sell | Open Market | 8,231 | $29K | 9/25/2023 |
| Daniel Karlin | ▼ Sell | Open Market | 3,678 | $13K | 9/25/2023 |
| Daniel Karlin | ▼ Sell | Open Market | 3,240 | $12K | 9/25/2023 |
| Greenway Schond L. | ▼ Sell | Open Market | 1,908 | $7K | 9/25/2023 |
| Greenway Schond L. | ▼ Sell | Open Market | 3,854 | $14K | 9/25/2023 |
| Greenway Schond L. | ▼ Sell | Open Market | 20,000 | $76K | 8/25/2023 |
| Robert Barrow | ▼ Sell | Open Market | 7,086 | $23K | 6/27/2023 |
| Robert Barrow | ▼ Sell | Open Market | 8,416 | $27K | 6/27/2023 |
| Daniel Karlin | ▼ Sell | Open Market | 3,820 | $12K | 6/27/2023 |
| Daniel Karlin | ▼ Sell | Open Market | 2,963 | $10K | 6/27/2023 |
| Greenway Schond L. | ▼ Sell | Open Market | 7,694 | $25K | 6/27/2023 |
| Greenway Schond L. | ▼ Sell | Open Market | 3,941 | $13K | 6/27/2023 |
| David W. Gryska | ▲ Buy | Grant | 13,851 | $0 | 6/21/2023 |
| Roger Crystal | ▲ Buy | Grant | 13,671 | $0 | 6/21/2023 |
| Andreas Krebs | ▲ Buy | Grant | 13,671 | $0 | 6/21/2023 |
| Carol A. Vallone | ▲ Buy | Grant | 13,671 | $0 | 6/21/2023 |
| Suzanne Louise Bruhn | ▲ Buy | Grant | 13,671 | $0 | 6/21/2023 |
| Mark Sullivan | ▲ Buy | Grant | 200,000 | $0 | 4/13/2023 |
| Robert Barrow | ▲ Buy | Grant | 400,000 | $0 | 3/14/2023 |
| Liao Carrie | ▲ Buy | Grant | 75,000 | $0 | 3/14/2023 |
| Daniel Karlin | ▲ Buy | Grant | 125,000 | $0 | 3/14/2023 |
| Wernli Miri Halperin | ▲ Buy | Grant | 100,000 | $0 | 3/14/2023 |
| Greenway Schond L. | ▲ Buy | Grant | 175,000 | $0 | 3/14/2023 |
| Daniel Karlin | ▼ Sell | Open Market | 3,577 | $13K | 3/1/2023 |
| Robert Barrow | ▼ Sell | Open Market | 8,273 | $29K | 3/1/2023 |
| Robert Barrow | ▼ Sell | Open Market | 3,861 | $10K | 12/21/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 1,211 | $3K | 12/21/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 644 | $2K | 10/27/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 541 | $2K | 10/25/2022 |
| Robert Barrow | ▼ Sell | Open Market | 1,207 | $3K | 10/25/2022 |
| Robert Barrow | ▼ Sell | Open Market | 1,220 | $4K | 10/18/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 640 | $4K | 9/27/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 565 | $3K | 9/26/2022 |
| Robert Barrow | ▼ Sell | Open Market | 1,264 | $7K | 9/26/2022 |
| Robert Barrow | ▼ Sell | Open Market | 1,350 | $10K | 9/16/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 1,204 | $14K | 8/31/2022 |
| Robert Barrow | ▼ Sell | Open Market | 1,228 | $14K | 8/31/2022 |
| Robert Barrow | ▼ Sell | Open Market | 20,350 | $14K | 8/16/2022 |
| Roger Crystal | ▲ Buy | Grant | 89,286 | $0 | 8/11/2022 |
| Suzanne Louise Bruhn | ▲ Buy | Grant | 89,286 | $0 | 8/11/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 9,856 | $7K | 7/27/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 8,361 | $6K | 7/25/2022 |
| Robert Barrow | ▼ Sell | Open Market | 18,681 | $13K | 7/25/2022 |
| Robert Barrow | ▼ Sell | Open Market | 19,388 | $14K | 7/18/2022 |
| Robert Barrow | ▼ Sell | Open Market | 36,762 | $26K | 6/27/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 26,238 | $18K | 6/27/2022 |
| Robert Barrow | ▼ Sell | Open Market | 21,275 | $15K | 6/16/2022 |
| Carol A. Vallone | ▲ Buy | Grant | 43,104 | $0 | 6/1/2022 |
| Brigid Makes | ▲ Buy | Grant | 64,656 | $0 | 6/1/2022 |
| Andreas Krebs | ▲ Buy | Grant | 21,552 | $0 | 6/1/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 9,555 | $8K | 5/27/2022 |
| Robert Barrow | ▼ Sell | Open Market | 18,415 | $14K | 5/25/2022 |
| Daniel Karlin | ▼ Sell | Open Market | 8,242 | $6K | 5/25/2022 |
| Greenway Schond L. | ▲ Buy | Grant | 1,270,000 | $0 | 5/23/2022 |
| Robert Barrow | ▼ Sell | Tax Withholding | 18,948 | $16K | 5/15/2022 |
| Brigid Makes | ▼ Sell | Other | 67,678 | $0 | 5/11/2022 |
| Daniel Karlin | ▼ Sell | Tax Withholding | 13,038 | $11K | 4/26/2022 |
| Robert Barrow | ▼ Sell | Tax Withholding | 19,110 | $18K | 4/18/2022 |
| Daniel Karlin | ▼ Sell | Tax Withholding | 10,203 | $12K | 3/28/2022 |
| Hu Cynthia W. | ▲ Buy | Grant | 1,200,000 | $0 | 3/24/2022 |
| Wernli Miri Halperin | ▲ Buy | Grant | 600,000 | $0 | 3/24/2022 |
| Daniel Karlin | ▲ Buy | Grant | 950,000 | $0 | 3/24/2022 |
| Robert Barrow | ▲ Buy | Grant | 1,820,000 | $0 | 3/24/2022 |
| Robert Barrow | ▼ Sell | Tax Withholding | 12,612 | $13K | 3/15/2022 |
| Daniel Karlin | ▼ Sell | Tax Withholding | 118,143 | $143K | 2/26/2022 |
| Robert Barrow | ▼ Sell | Tax Withholding | 18,734 | $25K | 2/15/2022 |
| Liao Carrie | ▲ Buy | Grant | 403,430 | $0 | 2/10/2022 |
| Robert Barrow | ▼ Sell | Tax Withholding | 190,287 | $200K | 1/15/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
JP Morgan Launches Coverage of DFTX with Overweight Rating
JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.
JP Morgan Launches Coverage of DFTX with Overweight Rating. JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.